Immunogenicity and Protective Efficacy of a Fusion Protein Vaccine Consisting of Antigen Ag85B and HspX against Mycobacterium tuberculosis Infection in Mice

Scandinavian Journal of Immunology

Volumn 73, Issue 6, 2011, Pages 568-576

  Li, Q ^a   Yu, H ^a   Zhang, Y ^a,b   Wang, B ^c   Jiang, W ^a   Da, Z ^a   Xian, Q ^d   Wang, Y ^d   Liu, X ^a   Zhu, B ^a  

^a LANZHOU UNIVERSITY   (China)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c LANZHOU INSTITUTE OF BIOLOGICAL PRODUCTS   (China)

^d WUHAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; HYBRID PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DETECTION; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; IMMUNOGENICITY; LUNG; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; TUBERCULOSIS; VACCINATION;

ACYLTRANSFERASES; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; COLONY COUNT, MICROBIAL; FEMALE; LUNG; MICE; MICE, INBRED BALB C; MYCOBACTERIUM TUBERCULOSIS; PLASMIDS; RECOMBINANT FUSION PROTEINS; SPECIFIC PATHOGEN-FREE ORGANISMS; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINES, SUBUNIT;

EID: 79955400032     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2011.02531.x     Document Type: Article

References (22)

1. Young DB, Gideon HP, Wilkinson RJ. Eliminating latent tuberculosis. Trends Microbiol 2009;17:183-8.
2. Andersen P. Vaccine strategies against latent tuberculosis infection. Trends Microbiol 2006;15:7-13.
3. Zhang Y. Advances in the treatment of tuberculosis. Clin Pharmacol Ther 2007;82:595-600.
4. Karakousis PC, Yoshimatsu T, Lamichhane G et al. Dormancy phenotype displayed by extracellular Mycobacterium tuberculosis within artificial granulomas in mice. J Exp Med 2004;200:647-57.
5. Flynn JL, Chan J. Immunology of tuberculosis. Annu Rev Immunol 2001;19:93-129.
6. Badell E, Nicolle F, Clark S et al. Protection against tuberculosis induced by oral prime with Mycobacterium bovis BCG and intranasal subunit boost based on the vaccine candidate Ag85B-ESAT-6 does not correlate with circulating IFN-γ producing T-cells. Vaccine 2009;27:28-37.
7. Sepulveda RL, Parcha C, Sorensen RU. Case-control study of the efficacy of BCG immunization against pulmonary tuberculosis in young adults in Santiago, Chile. Tuber Lung Dis 1992;73:372-7.
8. Fine PE. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995;346:1339-45.
9. Govender L, Abel B, Hughes EJ et al. Higher human CD4 T cell response to novel Mycobacterium tuberculosis latency associated antigens Rv2660 and Rv2659 in latent infection compared with tuberculosis disease. Vaccine 2010;29:51-7.
10. Saxena A, Srivastava V, Srivastava R, Srivastava BS. Identification of genes of Mycobacterium tuberculosis upregulated during anaerobic persistence by fluorescence and kanamycin resistance selection. Tuberculosis 2008;88:518-25.
11. Timm J, Post FA, Bekker LG et al. Differential expression of iron-, carbon-, and oxygen-responsive Mycobacterial genes in the lungs of chronically infected mice and tuberculosis patients. Proc Natl Acad Sci U S A 2003;100:14321-6.
12. Vekemans J, Ota MO, Sillah J et al. Immune responses to Mycobacterial antigens in the Gambian population: implications for vaccines and immunodiagnostic test design. Infect Immun 2004;72:381-8.
13. Caccamo N, Meraviglia S, La Mendola C et al. Characterization of HLA-DR and TCR-binding residues of an immunodominant and genetically permissive peptide of the 16-kDa protein of Mycobacterium tuberculosis. Eur J Immunol 2004;34:2220-9.
14. Gupta UD, Katoch VW, McMurray DN. Current status of TB vaccines. Vaccine 2007;25:3742-51.
15. Zhu B, Qie Y, Wang J et al. Chitosan microspheres enhance the immunogenicity of an Ag85B-based fusion protein containing multiple T-cell epitopes of Mycobacterium tuberculosis. Eur J Pharm Biopharm 2007;66:318-26.
16. 190-198-Mtb8.4 has higher immunogenicity than Ag85B with capacity to boost BCG-primed immunity against Mycobacterium tuberculosis in mice. Vaccine 2009;27:6179-85.
17. Maassen C, Boersma W, Holten-Neelen C, Claassen E, Laman J. Growth phase of orally administered Lactobacillus strains differentially affects IgG1/IgG2a ratio for soluble antigens: implications for vaccine development. Vaccine 2003;21:2751-7.
18. Fine PE. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995;346:1339-45.
19. Dietrich J, Lundberg CV, Andersen P. TB vaccine strategies - What is needed to solve a complex problem? Tuberculosis 2006;86:163-8.
20. Lee BY, Hefta SA, Brennan PJ. Characterisation of the major membrane protein of virulent Mycobacterium tuberculosis. Infect Immun 1992;60:2066-74.
21. Cunningham AF, Spreadbury CL. Mycobacterial stationary phase induced by low oxygen tension: cell wall thickening and localization of the 16-kilodalton alpha-crystallin homolog. J Bacteriol 1998;180:801.
22. Hoft DF. Tuberculosis vaccine development: goals, immunological design, and evaluation. Lancet 2008;372:164-75.